Mezagitamab

DB16370InvestigationalProtein Based Therapies

Mezagitamab is under investigation in clinical trial NCT04278924 (Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/chronic Primary Immune Thrombocytopenia).

Mechanism: Pharmacologically active on ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
Curator reviewed
Also known as: Anti-Cd38 monoclonal antibody TAK-079 · IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS ADP-RIBOSYL CYCLASE/CYCLIC ADP-RIBOSE HYDROLASE 1 (2'-PHOSPHO-ADP-RIBOSYL CYCLASE, ANTIGENE CD38))HUMANIZED MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN HUMANIZED(1-453) (HOMO SAPIENS VH (IGHV3-23*01 (89%) (IGHD)-I · IMMUNOGLOBULIN G1, ANTI-(HUMAN CD38 ANTIGEN) (HUMAN MONOCLONAL AB79 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL AB79 .LAMBDA.-CHAIN, DIMER
Code names: TAK-079 · WHO 11159

Resolves to

Compound

UNII0XMR8L9LOLCAS2227490-52-8

Targets

P28907CD38

What you can answer from here — as of August 01, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mezagitamab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account